Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

No benefit of covered vs uncovered self-expandable metal stents for malignant distal biliary obstruction

The latest issue of Clinical Gastroenterology & Hepatology compares covered vs uncovered self-expandable metal stents in patients with malignant distal biliary obstruction.

News image

Self-expandable metal stents (SEMS) are used in patients with malignant distal biliary obstruction.

Trials that compared covered and uncovered SEMS reported different results because of heterogeneous designs and patient populations.
 
These studies compared patency of uncovered SEMS and covered SEMS, along with rates of pancreatitis, cholecystitis, cholangitis, SEMS migration, bleeding, perforation, and recurrent biliary obstruction.

Dr Majid Almadi and colleagues from Canada performed a meta-analysis to compare the effects of covered and uncovered SEMS in patients with malignant distal biliary obstruction.

The researchers identified randomized controlled trials by using a literature search from 1980 through 2012.

The research team observed evaluated data from 5 full articles and 4 abstracts, comprising 1061 patients, and assessed statistical heterogeneity and publication bias.

The weighted mean difference in the stent patency duration could only be calculated on the basis of 2 studies, but it was 68 days longer for covered SEMS than for uncovered SEMS.

Patients with covered SEMS had a higher rate of tumor overgrowth
Clinical Gastroenterology & Hepatology

The doctors noted that a summary analysis of data from 4 trials demonstrated no differences in patency of covered vs uncovered SEMS after 6 months or 12 months.

There were also no differences in the rates of pancreatitis, cholecystitis, perforation, bleeding, or cholangitis, length of hospital stay, or number of recurrent biliary obstructions.

The researches found that covered SEMS had a higher migration rate.

Patients with covered SEMS had a lower rate of tumor ingrowth but a higher rate of tumor overgrowth.

The research team reported that no summary calculations could be completed to confidently assess patient survival.

Dr Almadi's team concluded, "The use of covered SEMS, compared with uncovered SEMS, in patients with distal malignant biliary obstruction is of unclear benefit."

"Covered SEMS have a higher rate of migration and do not appear to have longer patency."

Clin Gastroenterol Hepatol 2013:(11)1:27-37
14 January 2013

Go to top of page Email this page Email this page to a colleague

 05 September 2015

Advanced search
 04 September 2015 
HCV treatment in advanced liver disease
 04 September 2015 
IVF in women with IBD
 04 September 2015 
Crohn's disease of the esophagus
 03 September 2015 
Factors that influence GI transit with the wireless motility capsule
 03 September 2015 
Antibiotic resistance of H. pylori
 03 September 2015 
NAFLD in adolescents undergoing bariatric surgery
 02 September 2015 
Anxiety and functional dyspepsia
 02 September 2015 
Cancer predisposition genes in suspected Lynch syndrome
 02 September 2015 
Adherence to a gluten-free diet in celiac disease
 01 September 2015 
Nonceliac wheat sensitivity and autoimmune disease
 01 September 2015 
Dysphagia after antireflux surgery
 01 September 2015 
Predict treatment success in ulcerative colitis
 31 August 2015 

Fecal microbiota transplantation in IBD

 31 August 2015 
Probiotics and liver transplantation
 31 August 2015 
Cancer incidence in Barrett's
 28 August 2015 
Statin use and survival in pancreatic cancer
 28 August 2015 
Bacterial endotoxin and NAFLD
 28 August 2015 
Interferon-free regimens for Hep C
 27 August 2015 
HCV in Egypt
 27 August 2015 
Liver abnormalities in celiac disease
 27 August 2015 
Gene expression for hepatocellular carcinoma
 26 August 2015 
Medical management of diverticular disease
 26 August 2015 
Treatment of erosive esophagitis
 26 August 2015 
Dermatological complications of anti-TNF therapy in IBD
 25 August 2015 
Markers for colorectal cancer screening
 25 August 2015 
Long-term PPI use and serum gastrin levels
 25 August 2015 
Treatment for HCV and HIV-1 co-infection
 24 August 2015 
Treatment for HCV and HIV-1 co-infection
 24 August 2015 
Cirrhosis in Hepatitis C patients
 24 August 2015 
Aspirin use and colorectal cancer survival
 21 August 2015 
Activity indexes in ulcerative colitis
 21 August 2015 
Coffee and gallstone disease
 21 August 2015 
Alcoholic cirrhosis in relapse after liver transplant
 20 August 2015 
Cirrhosis in the USA
 20 August 2015 
Mortality causes in liver cirrhosis
 20 August 2015 
Risk of death in IBD
 19 August 2015 
Predicting intestinal surgery in Crohn's disease
 19 August 2015 
Sleep positioning device reduces reflux
 19 August 2015 
Improved screening colonoscopy quality
 18 August 2015 
Health insurance influences HCV screening outcomes
 18 August 2015 
Somatostatin analogues in polycystic liver disease
 18 August 2015 
Global consensus report on H. pylori gastritis
 17 August 2015 
Biomarker of fibrosis stage in NAFLD
 17 August 2015 
Prognostic score for primary biliary cirrhosis
 17 August 2015 
Measuring subjective health in patients with IBS
 14 August 2015 
Factors that influence ulcerative colitis procedure type
 14 August 2015 
H. pylori in African American and Hispanic veterans
 14 August 2015 
Hep E virus in decompensated chronic liver disease
 13 August 2015 
H. pylori in drinking water
 13 August 2015 
Sofosbuvir-regimens in HCV
 13 August 2015 
IBS among Japanese adolescents
 12 August 2015 
Infliximab in patients in IBD
 12 August 2015 
Predictors of severity of IBD
 12 August 2015 
Peritoneal carcinomatosis in colorectal cancer
 11 August 2015 
Chemotherapy and intestinal microbiomes
 11 August 2015 
H. pylori and immune thrombocytopenic purpura
 11 August 2015 
Sexual dysfunction after rectal cancer treatment
 10 August 2015 
Predicting lymph node metastasis in T1 colorectal cancer
 10 August 2015 
Scoring systems to predict alcoholic hepatitis outcomes
 10 August 2015 
Sofosbuvir-based regimens in veterans with HCV

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us